8-K: Viatris Reports Solid 2023 Results, Announces $2 Billion Share Repurchase Program and 2024 Guidance

Viatris exceeded 2023 financial guidance, reporting $15.4 billion in total revenue and announcing a $2 billion share repurchase program, while also providing 2024 financial guidance.

Summary

• Viatris reported its fourth quarter and full year 2023 financial results, meeting its 2023 guidance for total revenues, adjusted EBITDA, and free cash flow.
• The company's total revenues for 2023 were $15.4 billion, with U.S. GAAP net earnings of $54.7 million, adjusted EBITDA of $5.1 billion, and free cash flow of $2.4 billion.
• Viatris saw its third consecutive quarter of operational revenue growth on a divestiture-adjusted basis in 2023 and expects this growth to continue into 2024.
• The company has added two Phase 3 assets, Selatogrel and Cenerimod, through a global research and development collaboration with Idorsia, both with blockbuster potential.
• Viatris completed $250 million in share repurchases in 2024 and increased its share repurchase authorization by an additional $1 billion, bringing the total to $2 billion.
• The Board of Directors maintained the dividend policy for 2024 at 48 cents per share and declared a first quarter dividend of 12 cents per share.
• For 2024, Viatris is guiding for total revenues between $15.25 billion and $15.75 billion, adjusted EBITDA between $4.8 billion and $5.1 billion, and free cash flow between $2.3 billion and $2.7 billion.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong financial results and strategic initiatives, but there are some concerns about lower U.S. GAAP earnings and slightly reduced revenue guidance for 2024. The increased share buyback and dividend policy are positive signals.

Positives

• Viatris met its financial guidance for 2023, demonstrating strong operational performance.
• The company achieved its third consecutive quarter of operational revenue growth, indicating a positive trend.
• The addition of two Phase 3 assets with blockbuster potential through the Idorsia collaboration is a significant growth opportunity.
• The increased share repurchase authorization and maintained dividend policy signal a commitment to returning capital to shareholders.
• Viatris generated strong and durable cash flow, enabling debt paydown, business development, and capital return.
• The company is in a strong financial position with a return to organic revenue growth.

Negatives

• U.S. GAAP net earnings for 2023 were only $54.7 million, significantly lower than the previous year.
• Total net sales declined by 1% on a U.S. GAAP basis for the quarter ended December 31, 2023.
• The company is not providing forward-looking guidance for U.S. GAAP net earnings or a quantitative reconciliation of its 2024 adjusted EBITDA guidance.
• The 2024 guidance for total revenues is slightly lower than the 2023 results.
• Adjusted EBITDA for 2023 was lower than the previous year.

Risks

• The company may not realize the intended benefits of its strategic initiatives, including divestitures and acquisitions.
• There is a risk that divestitures may not be completed on expected timelines or at all.
• The company's ability to bring new products to market could be impeded by regulatory or legal issues.
• Changes in laws, regulations, and policies could impact the company's operations.
• The company faces risks associated with global operations, including economic and political conditions.
• There are uncertainties regarding future demand, pricing, and reimbursement for the company's products.
• The company is exposed to risks related to competition and loss of market exclusivity for certain products.

Future Outlook

Viatris expects to see continued operational revenue growth in 2024 and is focused on balancing capital return to shareholders with investments in future growth. The company believes it is well-positioned for continued growth in 2024 and beyond.

Management Comments

• Viatris CEO Scott A. Smith stated that 2023 was an outstanding year with strong operational results and the company is executing on its vision for the next chapter.
• Viatris President Rajiv Malik expressed pride in the accomplishments to integrate, simplify, and stabilize the base business, noting strong results in 2023.
• Viatris CFO Sanjeev Narula highlighted the company's solid year, meeting financial guidance, and generating strong cash flow, which has enabled capital allocation commitments.

Industry Context

This announcement comes as the pharmaceutical industry is navigating a complex landscape of pricing pressures, generic competition, and the need for innovation. Viatris' focus on streamlining operations, returning capital to shareholders, and investing in R&D aligns with broader industry trends of efficiency and strategic growth.

Comparison to Industry Standards

• Viatris' revenue of $15.4 billion is comparable to other large generic pharmaceutical companies such as Teva Pharmaceuticals and Mylan (prior to the merger with Upjohn).
• The adjusted EBITDA of $5.1 billion is a key metric for assessing profitability in the pharmaceutical sector, and Viatris' performance is in line with expectations for a company of its size.
• The share repurchase program of $2 billion is a significant return of capital to shareholders, which is a common practice among mature pharmaceutical companies.
• The addition of two Phase 3 assets through the Idorsia collaboration is a strategic move to enhance the pipeline, similar to other companies seeking to diversify their product portfolios.
• The company's focus on operational efficiency and cost management is a common theme in the pharmaceutical industry, as companies seek to improve profitability in a competitive market.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and dividend payments.
• Employees may be impacted by restructuring and divestiture activities.
• Customers will continue to have access to Viatris' products.
• Suppliers may be affected by changes in the company's supply chain.
• Creditors will be reassured by the company's strong cash flow and commitment to maintaining its investment grade credit rating.

Next Steps

• Viatris will host a conference call and live webcast to review the financial results.
• The company will hold an R&D event on March 27, 2024, to discuss the Idorsia collaboration and other pipeline elements.
• Viatris will continue to execute its share repurchase program.
• The company will pay the first quarter dividend on March 18, 2024.

Key Dates

Keywords

Viatris, Financial Results, Share Repurchase, Dividend, Guidance, Adjusted EBITDA, Free Cash Flow, R&D Collaboration, Pharmaceuticals, Generics, Brands